bioMérieux

Equities

BIM

FR0013280286

Market Closed - Euronext Paris Other stock markets 16:55:00 21/01/2026 GMT			5-day change	1st Jan Change
104.40 ^EUR	+0.77%		-3.33%	-5.35%

01-20	TP ICAP Midcap Upgrades bioMérieux to Buy	MT
01-07	BioMérieux Slips Despite Intensifying Flu Season Across the Atlantic

Transcript : BioMérieux S.A. - Analyst/Investor Day

Published on 11/04/2025 at 07:20 pm GMT

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Welcome to the bioMérieux 2025 Third Quarter Sales Conference Call. The call will be structured in two parts. First, a presentation by bioMérieux Group

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about bioMérieux

01-20	TP ICAP Midcap Upgrades bioMérieux to Buy	MT
01-07	BioMérieux Slips Despite Intensifying Flu Season Across the Atlantic
12-04	Biomerieux Launches Leading Endocrinology Testing Offer Dedicated to Enhancing Equine Health	CI
12-04	BioMérieux Launches Two Dedicated Equine Tests
11-10	UBS Maintains Buy Rating on BioMérieux, Confirms Price Target
11-05	Oxford Nanopore and bioMérieux launch AmPORE-TB, a Research Use Only sequencing-based solution to rapidly characterize drug resistant-tuberculosis	CI
11-05	Analysts Maintain Buy Ratings on bioMérieux After Q3 Results
11-05	Invest Securities Upgrades bioMérieux to Buy	MT
11-05	BioMérieux: launches solution to identify antibiotic-resistant tuberculosis
11-05	BIOMÉRIEUX : Invest Securities upgrades stock after quarterly results
11-04	Biomérieux Q3 earnings miss prompts softer 2025 guidance
11-04	BioMérieux S.A. - Analyst/Investor Day
11-04	BioMérieux S.A. Provides Earnings Guidance for the Full Year 2025	CI
11-04	Stifel remains bullish on BioMérieux after trading update.
11-04	BioMérieux adjusts annual revenue growth forecast
11-04	Biomerieux cuts 2025 sales growth outlook to max. 6.5%	RE
22/10/25	CIC Market Solutions Upgrades bioMérieux to Buy, Boosts PT	MT
11/09/25	BioMérieux: UBS Raises Price Target
11/09/25	BIOMÉRIEUX : UBS raises target price
09/09/25	Altesa BioSciences, Inc. and bioMérieux Announces Collaboration for Altesa's Upcoming Phase 2B COPD Clinical Trial	CI
05/09/25	BioMérieux S.A., H1 2025 Earnings Call, Sep 04, 2025
05/09/25	BioMérieux: Invest Securities Downgrades Rating to Neutral
05/09/25	BIOMÉRIEUX : Invest Securities downgrades stock
05/09/25	Invest Securities Downgrades bioMérieux to Neutral, Lowers PT	MT
04/09/25	BioMérieux S.A. Reports Earnings Results for the Half Year Ended June 30, 2025	CI